AADI | Aadi Bioscience, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.8000 - 1.8800
52 Week Range	1.2100 - 5.70
Beta	0.32
Implied Volatility	405.67%
IV Rank	100.00%
Day's Volume	81,632
Average Volume	299,917
Shares Outstanding	24,614,800
Market Cap	46,275,824
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-02-16

Valuation
Profitability
Growth
Health
P/E Ratio	-0.77
Forward P/E Ratio	N/A
EPS	-2.43
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	70
Country	USA
Website	AADI

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

AADI's peers: ANEB, ADAG, ACRV, ANAB, MLYS, ANTX, AVTE, GRCL, THRX, GLUE, DSGN, ERAS, RZLT, RARE, CRNX, ARVN, RVMD, KURA, ACET, ADCT, GLTO, MRKR, RDUS, BLTE

*Chart delayed

Analyzing fundamentals for AADI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see AADI Fundamentals page.

Watching at AADI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AADI Technicals page.